symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
XENE,35.29,1.29554,372142,2263694695,0,31.79-43.75,0.31,Xenon Pharmaceuticals Inc.,USD,0001582313,CA98420N1050,98420N105,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.xenon-pharma.com,"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.","Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA",Healthcare,CA,203,16044843300,3650 Gilmore Way,Burnaby,BC,V5G 4W8,0.377004,38.027,https://financialmodelingprep.com/image-stock/XENE.png,2014-11-05,False,False,True,False,False
